rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), United Biomedical

Conditions

HIV Infections

Phase 1

A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects

CompletedNCT00002428

United BiomedicalHIV Infections

Updated: 2005-06-24

A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)

CompletedNCT00000775

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Target: 40Updated: 2005-06-24